Metalloproteinases, inflammation, and rheumatoid arthritis

Annals of the Rheumatic Diseases

Volumn 62, Issue SUPPL. 2, 2003, Pages 43-47

  Mohammed, F F ^a   Smookler, D S ^a   Khokha, R ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AGGRECANASE; ALPHA CHEMOKINE; BETA CHEMOKINE; CELL ADHESION MOLECULE; CHEMOKINE; CHLOROTRIANISENE; COLLAGENASE 3; CX3C CHEMOKINE; GELATINASE A; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE 14; METALLOPROTEINASE; MONOCYTE CHEMOTACTIC PROTEIN 3; SYNDECAN 1; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME;

AMINO TERMINAL SEQUENCE; ANGIOGENESIS; ARTICULAR CARTILAGE; CARBOXY TERMINAL SEQUENCE; CONFERENCE PAPER; EPITHELIUM CELL; EXTRACELLULAR MATRIX; INFLAMMATORY CELL; INFLAMMATORY INFILTRATE; LEUKOCYTE MIGRATION; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DEGRADATION; PROTEIN DOMAIN; RHEUMATOID ARTHRITIS; TENSILE STRENGTH; TISSUE INJURY;

ARTHRITIS, RHEUMATOID; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; METALLOPROTEASES; TISSUE INHIBITOR OF METALLOPROTEINASE-3;

EID: 0142218538     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.62.1.43     Document Type: Conference Paper

References (34)

1. Nothon C. Points of control in inflammation. Nature 2002;420:846-52.
2. Vu TH, Werb Z. Matrix metalloproteinases: effectors of development and normal physiology. Genes Dev 2000;14:2123-33.
3. Hojillo C, Mohammed F, Khokha R. Directing cell fate through matrix metalloproteinases during cancer progression. Br J Cancer (in press).
4. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-7.
5. Wilson CL, Ouellette AJ, Satchell DP, Ayabe T, Lopez-Boado YS, Stratman JL, et al. Regulation of intestinal alpha-defensin activation by the metalloproteinase matrilysin in innate host defense. Science 1999;286:113-17.
6. Li Q, Park PW, Wilson CL, Parks WC. Matrilysin shedding of syndecan-1 regulates chemokine mobilization and transepithelial efflux of neutrophils in acute lung injury. Cell 2002;111:635-46.
7. McQuibban GA, Gong JH, Tam EM, McCulloch CA, Clark-Lewis I, Overall CM. Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. Science 2000;289:1202-6.
8. McQuibban GA, Gong JH, Wong JP, Wallace JL, Clark-Lewis I, Overall CM. Matrix metalloproteinase processing of monocyte chemoattractant proteins generates CC chemokine receptor antagonists with anti-inflammatory properties in vivo. Blood 2002;100:1160-7.
9. McQuibban GA, Butler GS, Gong JH, Bendall L, Power C, Clark-Lewis I, et al. Matrix metalloproteinase activity inactivates the CXC chemokine stromal cell-derived factor-1. J Biol Chem 2001;276:43503-8.
10. Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta 2000;1477:267-83.
11. Yu WH, Yu S, Meng Q, Brew K, Woessner JF Jr. TIMP-3 binds to sulfated glycosaminoglycans of the extracellular matrix. J Biol Chem 2000;275:31226-32.
12. Langton KP, Barker MD, McKie N. Localization of the functional domains of human tissue inhibitor of metalloproteinases-3 and the effects of Sorsby's fundus dystrophy mutation. J Biol Chem 1998;273:16778-81.
13. Weber BHF, Vogt G, Pruett RC, Stohr H, Felbor U. Mutations in the tissue inhibitor of metalloproteinases-3 (TIMP3) in patients with Sorsby's fundus dystrophy. Nat Genet 1994;8:352-6.
14. Amour A, Slocombe PM, Webster A, Butler M, Knight CG, Smith BJ, et al. TNF-alpha converting enzyme (TACE) is inhibited by TIMP-3. FEBS Lett 1998;435:39-44.
15. Kashiwagi M, Tortorella M, Nagase H, Brew K. TIMP-3 is a potent inhibitor of aggrecanase 1 (ADAM-TS4) and aggrecanase 2 (ADAM-TS5). Biol Chem 2001;276:12501-4.
16. Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slock JL, Wolfson MF, et al. A metalloproteinase disintegrin that releases tumour-necrosis factor alpha from cells. Nature 1997;385:729-33.
17. Moss ML, Jin SL, Milla ME, Bickett DM, Burkhart W, Carter HL, et al. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. Nature 1997;385:733-6.
18. Butler D, Maini RN, Feldmann M, Brennan FM. Blockade of TNFα with chimeric anti-TNFα monoclonal antibody, cA2 reduces (IL-6 and IL-8) release in RA NMC cultures: a comparison with IL-1ra. Eur Cytokin Netwk 1995;6:225-30.
19. Bian ZM, Elner SG, Strieter RM, Kunkel SL, Lukacs NW, Elner VM. IL-4 potentiates IL-beta-and TNF-alpha-stimulated IL-8 and MCP-1 protein production in human retinal pigment epithelial cells. Curr Eye Res 1999;18:349-57.
20. Borden P, Heller RA. Transcriptional control of matrix metalloproteinases and the tissue inhibitors of matrix metalloproteinases. Crit Rev Eukaryot Gene Exp 1997;7:159-78.
21. Peschon JJ, Slack JL, Reddy P, Stocking KL, Sunnorborg SW, Lee DC, et al. An essential role for ectodomain shedding in mammalian development, Science 1998282:1281-4.
22. Reddy P, Slack JL, Davis R, Cerretti DP, Kozlosky CJ, Blanton RA, et al. Functional analysis of the domain structure of tumor necrosis factor-alpha converting enzyme. J Biol Chem 2000;275:14608-14.
23. Aderka D, Engelmann H, Maor Y, Brokebusch C, Wallach D. Stabilization of the biooctivity of tumor necrosis factor by its soluble receptors. J Exp Med 1992;175:323-9.
24. Higuchi M, Aggarwal BB. Modulation of two forms of tumor necrosis factor receptors and their cellular response by soluble receptors and their monoclonal antibodies. J Biol Chem 1992;267:20892-9.
25. Mort JS, Billington CJ. Articular cartilage and changes in arthritis: matrix degradation. Arthritis Res 2001;3:337-41.
26. Arner EC, Hughes CE, Decicco CP, Caterson B, Tortorella MD. Cytokine-induced cartilage proteoglycan degradation is mediated by aggrecanase Osteoarthritis Cartilage 1998;6:214-28.
27. Murphy G, Knauper V, Atkinson S, Butler G, English W, Mutton M, et al. Matrix metalloproteinases in arthritic disease. Arthritis Res 2002;4(suppl):S39-49.
28. Hashimoto G, Aoki T, Nakamura H, Tanzawa K, Okada Y. Inhibition of ADAMTS4 (aggrecanase-1) by tissue inhibitors of metalloproteinases (TIMP-1, 2, 3 and 4). FEBS Lett 2001;494:192-5.
29. Apte SS, Olsen BR, Murphy G. The gene structure of tissue inhibitor of metalloproteinases (TIMP)-3 and its inhibitory activities define the distinct TIMP gene family. J Biol Chem 1995;270:14313-18.
30. Knauper V, Lopez-Otin C, Smith B, Knight G, Murphy G. Biochemical characterization of human collagenase-3. J Biol Chem 1996;271:1544-50.
31. Arend WP. Physiology of cytokine pathways in rheumatoid arthritis. Arthritis Rheum 2001;45:101-6.
32. Garton KJ, Gough PJ, Blobel CP, Murphy G, Greoves DR, Dempsey PJ, et al. Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1). J Biol Chem 2001;276:37993-8001.
33. Ruth JH, Volin MV, Haines III GK, Woodruff DC, Katschke Jr KJ, Woods JM, et al. Fractalkine, a novel chemokine in rheumatoid arthritis and in rat adjuvant induced arthritis. Arthritis Rheum 2001;44:1568-81.
34. van der Laan WH, Quax PH, Seemayer CA, Huisman LG, Pieterman EJ, Grimbergen JM, et al. Cartilage degradation and invasion by rheumatoid synovial fibroblasts is inhibited by gene transfer of TIMP-1 and TIMP-3. Gene Ther 2003;10:234-42.